Imaging of Integrin α v β 3 Expression in Lung Cancers and Brain Tumors Using Single-Photon Emission Computed Tomography with a Novel Radiotracer 99m Tc-IDA-D-[c(RGDfK)] 2 .

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 9605408 Publication Model: Print Cited Medium: Internet ISSN: 1557-8852 (Electronic) Linking ISSN: 10849785 NLM ISO Abbreviation: Cancer Biother Radiopharm Subsets: MEDLINE
    • Publication Information:
      Original Publication: Larchmont, NY : Mary Ann Liebert, Inc., c1996-
    • Subject Terms:
      Angiogenesis Inhibitors/*therapeutic use ; Brain Neoplasms/*diagnostic imaging ; Lung Neoplasms/*diagnostic imaging ; Molecular Imaging/*methods ; Organotechnetium Compounds/*pharmacology ; Peptides, Cyclic/*pharmacology ; Radiopharmaceuticals/*pharmacology ; Tomography, Emission-Computed, Single-Photon/*methods; Aged ; Biomarkers, Tumor/metabolism ; Brain Neoplasms/drug therapy ; Brain Neoplasms/mortality ; Brain Neoplasms/pathology ; Disease-Free Survival ; Female ; Fluorodeoxyglucose F18/pharmacology ; Follow-Up Studies ; Glucose/metabolism ; Humans ; Image Processing, Computer-Assisted ; Integrin alphaVbeta3/metabolism ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Molecular Imaging/adverse effects ; Neovascularization, Pathologic/diagnostic imaging ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/pathology ; Organotechnetium Compounds/chemical synthesis ; Peptides, Cyclic/chemical synthesis ; Radiopharmaceuticals/chemical synthesis ; Tissue Distribution ; Tomography, Emission-Computed, Single-Photon/adverse effects ; Treatment Outcome
    • Abstract:
      Integrin α v β 3 is a molecular marker for the estimation of tumor angiogenesis and is an imaging target for radiolabeled Arg-Gly-Asp (RGD) peptides. In this study, the authors investigated the clinical efficacy and safety of a novel radiolabeled RGD peptide, 99m Tc-IDA-D-[c(RGDfK)] 2 , for the imaging of integrin α v β 3 expression, as a measure of tumor angiogenesis in lung cancers and brain tumors. Five patients with lung cancers and seven with brain tumors underwent 99m Tc-IDA-D-[c(RGDfK)] 2 single-photon emission computed tomography (SPECT) imaging. Tumors were also assessed using 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Uptake of the radiotracer was expressed as the tumor-to-normal uptake ratio (TNR). All the lung cancers and brain tumors were well visualized on 99m Tc-IDA-D-[c(RGDfK)] 2 SPECT. TNR for 99m Tc-IDA-D-[c(RGDfK)] 2 was significantly higher than that for 18 F-FDG in brain tumors (6.4 ± 4.1 vs. 0.9 ± 0.4). Proliferation index of brain tumors showed a significant positive correlation with TNR for 99m Tc-IDA-D-[c(RGDfK)] 2 and 18 F-FDG. No laboratory and clinical adverse events were reported after 99m Tc-IDA-D-[c(RGDfK)] 2 injection. Their results suggest that 99m Tc-IDA-D-[c(RGDfK)] 2 is an efficacious and safe radiotracer for imaging integrin α v β 3 expression with potential application to monitoring the clinical efficacy of antiangiogenic agents in malignant tumors. In addition, this is the first clinical application of radiolabeled RGD peptides for SPECT imaging of brain tumors.
    • References:
      Science. 1994 Apr 22;264(5158):569-71. (PMID: 7512751)
      Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2029-37. (PMID: 26153145)
      Brain Pathol. 2008 Jul;18(3):378-86. (PMID: 18394009)
      Curr Pharm Des. 2004;10(13):1439-55. (PMID: 15134568)
      Mol Aspects Med. 2012 Oct-Dec;33(5-6):579-89. (PMID: 22387049)
      Bioconjug Chem. 2004 Jan-Feb;15(1):61-9. (PMID: 14733584)
      Int J Clin Exp Pathol. 2015 Dec 01;8(12 ):16064-72. (PMID: 26884883)
      Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S126-38. (PMID: 22388629)
      J Nucl Med. 2008 Jan;49(1):22-9. (PMID: 18077538)
      Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1303-12. (PMID: 21487838)
      Theranostics. 2016 Jan 01;6(1):78-92. (PMID: 26722375)
      Bioconjug Chem. 2008 Dec;19(12):2409-16. (PMID: 18998719)
      Angiogenesis. 2010 Jun;13(2):71-4. (PMID: 20559867)
      Theranostics. 2011 Jan 18;1:58-82. (PMID: 21547153)
      Bioconjug Chem. 2004 Jan-Feb;15(1):41-9. (PMID: 14733582)
      J Nucl Med. 2012 Dec;53(12):1872-7. (PMID: 23071350)
      Nat Rev Cancer. 2002 Feb;2(2):83-90. (PMID: 12635171)
      Cancer Res. 2000 Jan 15;60(2):203-12. (PMID: 10667560)
      Am J Physiol Cell Physiol. 2001 Jun;280(6):C1358-66. (PMID: 11350730)
      Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S78-92. (PMID: 22388627)
      J Nucl Med. 2012 May;53(5):716-22. (PMID: 22499615)
      Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):46-52. (PMID: 20711577)
      Mol Pharm. 2014 Nov 3;11(11):3923-9. (PMID: 25093246)
      J Nucl Med. 2015 Dec;56(12 ):1823-7. (PMID: 26429958)
      Clin Cancer Res. 2008 Nov 15;14 (22):7330-9. (PMID: 19010848)
      Brain Tumor Pathol. 2011 Feb;28(1):13-24. (PMID: 21221826)
      FASEB J. 1999 Jan;13(1):9-22. (PMID: 9872925)
      Sci Rep. 2015 Jun 30;5:11752. (PMID: 26123253)
      Neuro Oncol. 2009 Dec;11(6):861-70. (PMID: 19401596)
      Radiology. 2016 Dec;281(3):958-966. (PMID: 27479638)
    • Contributed Indexing:
      Keywords: 99mTc-IDA-D-[c(RGDfK)]2; brain tumor; integrin αvβ3 expression; lung cancer; single-photon emission computed tomography
    • Accession Number:
      0 (99mTc-IDA-D-(c(RGDfK))2)
      0 (Angiogenesis Inhibitors)
      0 (Biomarkers, Tumor)
      0 (Integrin alphaVbeta3)
      0 (Organotechnetium Compounds)
      0 (Peptides, Cyclic)
      0 (Radiopharmaceuticals)
      0Z5B2CJX4D (Fluorodeoxyglucose F18)
      IY9XDZ35W2 (Glucose)
    • Publication Date:
      Date Created: 20171021 Date Completed: 20180612 Latest Revision: 20191210
    • Publication Date:
      20240513
    • Accession Number:
      PMC5661893
    • Accession Number:
      10.1089/cbr.2017.2233
    • Accession Number:
      29053416